These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28789805)

  • 1. Reply to Parham Habibzadeh and Farrokh Habibzadeh's Letter to the Editor re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. Eur Urol 2017;72:942-9. The Most Appropriate IsoPSA Cutoff for Diagnosis of Prostate Cancer.
    Klein EA
    Eur Urol; 2017 Dec; 72(6):e174. PubMed ID: 28789805
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. Eur Urol 2017;72:942-9: The Most Appropriate IsoPSA Cutoff for Diagnosis of Prostate Cancer.
    Habibzadeh P; Habibzadeh F
    Eur Urol; 2017 Dec; 72(6):e172-e173. PubMed ID: 28687145
    [No Abstract]   [Full Text] [Related]  

  • 3. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report.
    Klein EA; Chait A; Hafron JM; Kernen KM; Manickam K; Stephenson AJ; Wagner M; Zhu H; Kestranek A; Zaslavsky B; Stovsky M
    Eur Urol; 2017 Dec; 72(6):942-949. PubMed ID: 28396176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's letter to the editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur urol 2014;66:550-60.
    Klein EA; Cooperberg MR; Carroll PR
    Eur Urol; 2014 Dec; 66(6):e117-8. PubMed ID: 25150174
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54.
    Mahal BA; Yang DD; Nguyen PL
    Eur Urol; 2018 Nov; 74(5):e112-e113. PubMed ID: 30029822
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7.
    Vickers AJ; Lilja H; Assel M
    Eur Urol; 2019 Mar; 75(3):e56. PubMed ID: 30327273
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett Delahunt's Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1.
    Zietman A; Smith J; Klein E; Droller M; Dasgupta P; Catto J
    Eur Urol; 2017 Feb; 71(2):e54. PubMed ID: 27452952
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7.
    Gandaglia G; Fossati N; Montorsi F; Briganti A
    Eur Urol; 2018 May; 73(5):e131-e132. PubMed ID: 29395499
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Alan Dal Pra, Stephane Supiot and Pirus Ghadjar's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7.
    Gandaglia G; Fossati N; Montorsi F; Briganti A
    Eur Urol; 2018 Feb; 73(2):e36-e37. PubMed ID: 28890246
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Joshua S. Jue and Mahmoud Alameddine's Letter to the Editor re: Juha Knaapila, Ivan Jambor, Ileana Montoya Perez, et al. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. Eur Urol Oncol 2020;3:648-656.
    Knaapila J; Jambor I; Falagario U; Ettala O; Syvänen KT; Boström PJ
    Eur Urol Oncol; 2020 Oct; 3(5):711-712. PubMed ID: 31882349
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Takeshi Takahashi's Letter to the Editor re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol 2021;80:703-711: Would You Play a Russian Roulette-type Game of Prostate-specific Antigen Screening on Yourself?
    Van Poppel H; Roobol MJ
    Eur Urol; 2022 Jan; 81(1):e23-e24. PubMed ID: 34756628
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Rescigno P; de Bono JS
    Eur Urol; 2016 Dec; 70(6):e170-e171. PubMed ID: 27240941
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Runqiang Yuan and Hongxing Huang's Letter to the Editor re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Eur Urol 2016;69:214-20.
    Sivaraman A; Barret E
    Eur Urol; 2017 May; 71(5):e148-e149. PubMed ID: 28161029
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur urol 2014;66:550-60.
    Tolkach Y; Kuczyk M; Imkamp F
    Eur Urol; 2014 Dec; 66(6):e115-6. PubMed ID: 25139198
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Arnaldo Stanzione, Massimo Imbriaco, and Renato Cuocolo's Letter to the Editor re: Marloes van der Leest, Bas Israël, Eric Bastiaan Cornel, et al. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. Eur Urol 2019;76:574-81. Are We Meeting Our Standards? Stringent Prostate Imaging Reporting and Data System Acquisition Requirements Might be Limiting Prostate Accessibility.
    Leest MV; Israël B; Engels RRM; Barentsz JO
    Eur Urol; 2020 Mar; 77(3):e58-e59. PubMed ID: 31818520
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178-211.
    Gillessen S; de Bono JS; Sartor O; Omlin AG
    Eur Urol; 2018 Feb; 73(2):e32-e33. PubMed ID: 28869069
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Michael Froehner, Manfred P. Wirth's letter to the editor re: Jim C. Hu, Giorgio Gandaglia, Pierre I. Karakiewicz, et al. Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control. Eur Urol 2014;66:666-72.
    Hu JC
    Eur Urol; 2014 Nov; 66(5):e86. PubMed ID: 24882671
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Yaalini Shanmugabavan, Stephanie Guillaumier and Hashim U. Ahmed's letter to the editor re: Morgan R. Pokorny, Maarten de Rooij, Earl Duncan, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2014;66:22-9.
    Pokorny M; Van de Ven W; Barentsz J; Thompson L
    Eur Urol; 2015 Mar; 67(3):e54-5. PubMed ID: 25194908
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Sandra Patricia García Nader, Sebastián Peña Rodríguez, and Cesar Alejandro Diaz Ritter's Letter to the Editor re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol. 2023;83:48-54.
    Nik-Ahd F; Cooperberg MR; Freedland SJ
    Eur Urol; 2023 Apr; 83(4):e104. PubMed ID: 36653258
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7.
    Penney KL; Loda M; Stampfer MJ
    Eur Urol; 2019 Mar; 75(3):e54-e55. PubMed ID: 30322655
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.